Nasdaq:US$19.68 (-0.41) | HKEX:HK$31.40 (-0.65) | AIM:£3.13 (-0.11)
Other Ventures
Separate from our Oncology/Immunology R&D and commercial operations, our Other Ventures segment operates in several countries in south-east Asia.

It mainly consists of:

  • Shanghai Hutchison Pharmaceuticals, a non-consolidated joint venture with a commercial team of about 2,200 staff managing the medical detailing and marketing of a range of own-brand prescription drug products across mainland China. This 50/50 joint venture is with Shanghai Pharmaceuticals, a leading pharmaceutical company in China.
  • Hutchison Sinopharm, a consolidated joint venture focused on providing commercial services for our own marketed drugs, as well as marketing third-party prescription drug products. This joint venture is 51% owned by HUTCHMED and 49% owned by Sinopharm, a leading distributor of pharmaceutical and healthcare products and a leading supply chain service provider in China.
  • Hutchison Healthcare, a wholly owned subsidiary which was established in 2001 and manufactures and sells health supplements.